Occurrence of Comorbidities before and after Soft Tissue Sarcoma Diagnosis
Table 3
Incidence rates of comorbidities* stratified by followup time since diagnosis of soft tissue sarcoma, compared to a noncancer population.
Patients with soft tissue sarcoma
Cancer-free control cohort
Hazard ratio
Events
Followup
IR per 1,000
Events
Followup
IR per 1,000
(95% CI)
PY
PY (95% CI)
PY
PY (95% CI)
0 to 6 months after diagnosis
Cardiovascular disease
20
161
124 (75–193)
72
2,004
36 (28–45)
3.7 (2.1–6.3)
Respiratory disease
3
220
14 (5–41)
30
2,444
12 (8–18)
1.1 (0.3–3.7)
Diabetes
2
226
9 (0–31)
9
2,473
4 (2–7)
2.5 (0.5–11.5)
Anemia
19
224
85 (49–134)
31
2,527
12 (8–17)
6.9 (3.8–12.4)
Depression
9
226
40 (18–75)
31
2,486
12 (8–18)
3.2 (1.5–6.9)
6 to 12 months after diagnosis
Cardiovascular disease
8
143
56 (21–112)
52
1,841
28 (21–37)
2.6 (1.2–5.9)
Respiratory disease
4
195
21 (5–51)
16
2,265
7 (4–11)
2.5 (0.8–7.6)
Diabetes
1
202
5 (0–30)
13
2,298
6 (3–10)
0.8 (0.1–6.5)
Anemia
7
194
36 (15–72)
18
2,344
8 (5–12)
5.4 (2.1–13.6)
Depression
1
198
5 (0–30)
23
2,301
10 (7–15)
0.5 (0.1–3.8)
12 months after diagnosis to total followup
Cardiovascular disease
29
762
38 (25–55)
292
10,594
28 (24–31)
1.4 (0.9–2.1)
Respiratory disease
14
1,042
13 (8–22)
78
13,491
6 (5–7)
2.2 (0.9–4.0)
Diabetes
9
1,106
8 (4–15)
69
13,804
5 (4–6)
1.6 (0.8–3.2)
Anemia
12
1,063
11 (6–20)
75
14,036
5 (4–7)
2.3 (1.2–4.4)
Depression
14
1,076
13 (7–21)
91
13,655
7 (5–8)
2.0 (1.1–3.7)
PY: person-years; IR: incidence rate; 95% CI: 95% confidence interval; *comorbidity defined as either at least 2 dispensings of a relevant drug or a hospitalization for that condition after soft tissue sarcoma diagnosis.
